Prosecution Insights
Last updated: November 19, 2026
Application No. 18/906,207

IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Oct 04, 2024
Priority
Sep 27, 2021 — provisional 63/248,566 +3 more
Examiner
PECKHAM, RICHARD GRANT
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Janssen Pharmaceutica N.V.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
1y 2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
97 granted / 143 resolved
+7.8% vs TC avg
Strong +36% interview lift
Without
With
+35.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
60 currently pending
Career history
208
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
28.7%
-11.3% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
30.7%
-9.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 143 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, 60, 92-93, and 112-113 are currently pending. Election/Restriction Applicant’s election without traverse of Group I (Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, and 60, drawn to compounds of Formula (I)) and the elected species: PNG media_image1.png 171 251 media_image1.png Greyscale in the reply filed on 9/28/2026 is acknowledged. Claims 92-93, and 112-113 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected Group II or unelected species, there being no allowable generic or linking claim. Thus, Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, and 60 are being examined on the merits herein. The requirement is deemed proper and is therefore made final. The elected species was searched and found to be free of the art. Compounds of Formula 1 (according to both the Claim 1 and Claim 6 genera) were searched. Information Disclosure Statement The information disclosure statement(s) submitted on 3/19/2026 has not been signed “by an applicant or representative” as required (Page 4). Accordingly, the information disclosure statement has not been considered by the examiner. Claim Objections Claim 6 is objected to because of the following informalities: Claim 6 is drawn to a compound of “Formula (I)” which is a different genus from the “Formula (I)” of Claim 1, which is a separate independent claim. Alternative naming is required to distinguish the different “Formula (I)” genera belonging to two different independent claims. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 15 and 26 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. The latest amendments filed on 9/28/2026 strike “1” from the preambles. As amended, it is unclear which claim Claims 15 or 26 depend upon. In view of the “previously presented” status, and for the purpose of compact prosecution, the preamble of each claim is interpreted for examination to read as follows: “The compound of claim 1”. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 3-9, 14-15, 19, 21, 26, 37, and 42 are rejected under 35 U.S.C. 103 as being unpatentable over Coates (WO2020146194, published 1/03/2020; 12/11/2024 IDS). Coates teaches IL-17A inhibitors (Abstract). Coates teaches Example 24 on Page 106: PNG media_image2.png 209 331 media_image2.png Greyscale , which differs only from the elected species PNG media_image3.png 177 249 media_image3.png Greyscale as follows: (1) R2 of CH2O-cyclopropyl is instead CH2OCH3; and (2) the R1 of PNG media_image4.png 117 74 media_image4.png Greyscale is instead PNG media_image5.png 140 84 media_image5.png Greyscale , wherein m1 is 0, n is 1, R1b is thrice fluoro-substituted C1alkyl, m2 is 1, and the carbon to which (R1a)m3 is attached is missing. Instant Claim 21 of the examined invention explicitly teaches the Coates CH2OCH3 is an acceptable Formula (I) group: PNG media_image6.png 30 50 media_image6.png Greyscale . Coates does not teach an additional ring methylene between a ring nitrogen and the carbon possessing a haloalkyl substituent. However, compounds which are homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups like the 2-imidazolinone ring of Coates and the instant 2-tetrahydropyrimidinone) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). See MPEP 2144.09. Therefore, one of skill in the art seeking to form an IL-17A inhibitor before the effective filing date of the present invention would have found it obvious to insert a methylene into the Coates ring, yielding a moiety as follows: PNG media_image7.png 99 67 media_image7.png Greyscale (ring group found in instant Claim 15). The same artisan would expect a successful inhibitor to result because homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”. The elected species differs from the Coates compound by its R2 group, number of R1 ring members, and R1 substituent groups. No suggestion is made to modify the R1 ring to comport with that of the elected species or those species depicted in Claim 60. For these reasons, Claim 60 is not rejected. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. PROVISIONAL: Claims 1, 3-9, 14-15, 19, 21, 26, 37, and 42 are provisionally rejected on the grounds of nonstatutory double patenting as being unpatentable over Claims 1, 16, 22, 25, 32-34, 37-39, 43, 45, 48, 74, 76-80 (Claims according to 10/27/2026 response filed) of copending Application No. 18973307 (hereinafter referred to as Goldberg). Although the claims at issue are not identical, they are not patentably distinct from each other because both applications are directed to a genus of IL-17 inhibitors of an instant formula PNG media_image8.png 315 459 media_image8.png Greyscale and a formula of the copending claims PNG media_image9.png 278 430 media_image9.png Greyscale . Goldberg recites similar functional groups to the instant with the narrower embodiments as follows: R2 of PNG media_image10.png 64 307 media_image10.png Greyscale (Claim 16). R3 of PNG media_image11.png 44 95 media_image11.png Greyscale (Claim 34) R4 of PNG media_image12.png 84 387 media_image12.png Greyscale R1 can be PNG media_image13.png 68 78 media_image13.png Greyscale (Claim16), which differs from the examined embodiment of Claim 15 PNG media_image14.png 67 69 media_image14.png Greyscale by a single methylene. Regarding the single difference between the respective R1 groups, compounds which are homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups like the 2-imidazolinone ring of Coates and the instant 2-tetrahydropyrimidinone) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). See MPEP 2144.09. Therefore, one of skill in the art seeking to form an IL-17 inhibitor according to the Goldberg formula would have found it obvious to insert a methylene into the ring, resulting in an R1 as shown in instant Claim 15: PNG media_image14.png 67 69 media_image14.png Greyscale . The same artisan would expect a successful inhibitor to result because homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”. Copending claims drawn to methods of using the compounds require the existence of the similar homologous compounds over which the instant claims are rejected. Since both applications teach IL-17 inhibitors of the same core, the examiner maintains that the aforementioned claims of the instant application are substantially overlapping in scope as discussed hereinabove and are prima facie obvious over the cited claims of Goldberg. This is a provisional nonstatutory double patenting rejection. NONPROVISIONAL: Claims 1, 3-9, 14-15, 19, 21, 26, 37, and 42 are provisionally rejected on the grounds of nonstatutory double patenting as being unpatentable over Claims 1-3, 5-9, 11-15, 18-20, and 22-24 of U.S. Patent No. 12215111 (hereinafter referred to as Goldberg). Although the claims at issue are not identical, they are not patentably distinct from each other because both applications are directed to IL-17 inhibitors of the same core. Goldberg teaches several compounds having the same core as those of the instant Formula (I). For example, Goldberg teaches the following compound in Claim 1: PNG media_image15.png 177 284 media_image15.png Greyscale , in which the following definitions of examined Formula (I) apply: R2 is PNG media_image16.png 36 26 media_image16.png Greyscale , R3 is PNG media_image17.png 67 85 media_image17.png Greyscale , R4 is a 5-membered heteroaryl with three heteroatoms selected from O and N, substituted by one R4a, which is a C1alkyl. Only R1 differs in that the compound above and those of Goldberg generally lack an additional ring methylene member. However, compounds which are homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups like the 2-imidazolinone ring of Coates and the instant 2-tetrahydropyrimidinone) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). See MPEP 2144.09. Therefore, one of skill in the art seeking to form an IL-17 inhibitor homolog of the Goldberg compounds would find it obvious to insert a methylene into the ring, resulting in an R1 as shown in instant Claim 15: PNG media_image14.png 67 69 media_image14.png Greyscale or PNG media_image18.png 94 70 media_image18.png Greyscale , for example. The same artisan would expect a successful inhibitor to result because homologs “are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties”. Since both claim sets teach IL-17 inhibitors, the examiner maintains that the aforementioned claims of the instant application are substantially overlapping in scope as discussed hereinabove and are prima facie obvious over the cited claims of Goldberg. Claims 1, 3-9, 14-15, 19, 21, 26, 37, 42, and 60 are rejected on the grounds of nonstatutory double patenting as being unpatentable over Claims 1-11, 13-14, 16-29, and 31-32 of U.S. Patent No. 12173007 (hereinafter referred to as Goldberg). Although the claims at issue are not identical, they are not patentably distinct from each other because both applications are directed to IL-17 inhibitors. Goldberg teaches several compounds which anticipate the instant Formula (I), the compounds listed in Claim 60, and the elected species. For example, the elected species is taught in Claim 1 of Goldberg: PNG media_image19.png 189 291 media_image19.png Greyscale Since both claim sets teach the same compounds, the examiner maintains that the aforementioned claims of the instant application are substantially overlapping in scope as discussed hereinabove and are anticipated by the cited claims of Goldberg. Conclusion No claim is allowable. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Peckham whose telephone number is (703)756-4621. The examiner can normally be reached 8:30am - 4:30pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD GRANT PECKHAM/Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Oct 04, 2024
Application Filed
Nov 03, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773403
SCOPOLAMINE COMPOSITIONS AND TRANSDERMAL PATCHES MADE THERRFROM
5y 1m to grant Granted Oct 27, 2026
Patent 12773401
Pharmaceutical compositions of Ovatodiolide and the use thereof
4y 10m to grant Granted Oct 27, 2026
Patent 12774277
AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
3y 5m to grant Granted Oct 27, 2026
Patent 12748101
COMPOSITION AND METHOD FOR INHIBITING BORC COMPLEX TO TREAT CANCERS WITH NF1 DEFICIENCY AND DYSREGULATED RAS SIGNALING
4y 6m to grant Granted Sep 29, 2026
Patent 12735425
6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT
3y 3m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+35.9%)
3y 3m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 143 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month